Can psychedelic compounds play a part in drug dependence therapy?
The British Journal of Psychiatry January 1, 2015 DOI: 10.1192/bjp.bp.114.148031 via OpenAlex
Summary
AI-generated from the abstractAfter a 40-year pause, psychiatric research is revisiting psychedelic drug therapy, with studies examining psilocybin, ketamine, ibogaine, and ayahuasca for treating drug dependence. Clinical and legal limitations exist, but the potential to improve outcomes for patients with substance dependency creates an obligation to continue researching this area.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with substance dependency |
| Interventions | Psilocybin Ketamine Ibogaine Ayahuasca |
| Topics | Ayahuasca Ketamine Psilocybin |
| Keywords | Hallucinogen Drug |
| Citations | 58 |
| Key finding | Psychedelic drug therapy is being revisited in psychiatry for treating drug dependence, though clinical and legal limitations remain. |
Abstract
Summary After a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research this area.